Eplerenone (Inspra - Pfizer Canada Inc.) new indication: NYHA class II heart failure
CADTH
Record ID 32014000749
English
Authors' recommendations:
Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that eplerenone not be listed at the submitted price for patients with New York Heart Association (NYHA) class II systolic chronic heart failure.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0342_Inspra_Apr-28_14.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Heart Failure
- Spironolactone
- Mineralocorticoid Receptor Antagonists
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.